The double-blind, placebo-controlled study will investigate people with moderate to severe MDD. In May 2022, Cybin submitted the IND for the phase I/IIa study evaluating CYB003 for treating MDD.

Concordia's IT technicians will be making an upgrade available to all MDD users through the use of the Software Center. This upgrade is both a standalone product that can be installed without a prior ...

Meanwhile, a third group, previously skeptical about the epilepsy market, now finds the addition of MDD to Xenon’s portfolio more compelling, potentially offering an attractive return on investment.

--Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’ s disease, bipolar disorder, major depressive disorder and ...

People with major depressive disorder (MDD) feel more negative emotion when remembering painful experiences than people without the disorder, according to a new study in Biological Psychiatry ...

Major depressive disorder (MDD) is not only among the most common mental illnesses, affecting over 8% of Americans, but it is also extremely variable from one person to another.